New implant aims to ease neck pain from disc disease

NCT ID NCT06155409

Ongoing Disease control Sponsor: SPINEVISION SAS Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 148 adults with cervical disc disease who received the Hexanium ACIF implant, a device placed between vertebrae to restore height and fuse the spine. Researchers will track pain, disability, and any serious side effects for up to 24 months after surgery. The goal is to confirm the implant is safe and works as intended.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hexanium ACIF implant (a cage placed between vertebrae to restore height and fuse the spine)
What this could lead to: If successful, this could confirm that the Hexanium ACIF implant is a safe and effective option for treating cervical disc disease, reducing pain and disability.
What could go wrong: This is an observational study, not a randomized trial, so results may be less definitive. Risks include infection, implant failure, or no improvement in symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL SPINE DEGENERATIVE DISC DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ankylosis cervical disk degenerative disorder intervertebral disk degenerative disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTERVERTEBRAL DISC DEGENERATION

Contacts and locations

Locations

CHRU de Nancy

Nancy, 54000, France
Centre Hospitalier Privé de l'Europe

Le Port-Marly, 785620, France
Clinique du Dos Terrefort

Bordeaux, 33520, France
Hôpital Privé du Dos Francheville

Périgueux, 24000, France
Hôpital Robert Schuman - UNEOS

Vantoux, 57070, France
Polyclinique Majorelle

Nancy, 54000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.